Impraon-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and other acid-related gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and reducing acid reflux. The synergistic action of these agents provides effective symptomatic relief and enhances mucosal protection in patients with erosive esophagitis and non-erosive reflux disease. Impraon-DSR is typically administered orally once daily, preferably before meals, to optimize therapeutic outcomes. Caution is advised in patients with known hypersensitivity to either component, and it should be used judiciously in individuals with hepatic impairment or prolactinoma. Common adverse effects may include headache, dry mouth, and abdominal discomfort. This combination therapy should be prescribed under medical supervision, with periodic evaluation to assess efficacy and monitor for potential side effects. Impraon-DSR Capsule offers a comprehensive approach to managing acid-related gastrointestinal conditions by combining prokinetic and acid suppression mechanisms.